Charles S. Fuchs, MD, MPH
|Agent||Target||Trial||OS advantage versus control (months)|
|Rilotumumab||c-MET||Phase II studyc||5.4|
aPatients were randomized to capecitabine or 5-FU (physician’s choice) plus cisplatin or the same chemotherapy plus trastuzumab.
bPatients were randomized to ramucirumab versus placebo.
cOS benefit was observed in subset of patients with high MET expression who received rilotumumab plus ECX versus ECX alone.
... to read the full story